Lyerly Neurosurgery, Baptist Medical Center Downtown, Jacksonville, Florida, USA.
Interventional Neuroradiology Department, University Hospital Centre of Limoges, Limoges, France.
J Neurointerv Surg. 2023 Dec;15(12):1181-1186. doi: 10.1136/jnis-2023-020673. Epub 2023 Oct 16.
The anterior communicating artery (AComm) region is the most common site of intracranial aneurysms, with increased rupture risk compared with other locations. Overall, flow diverters present as a safe and efficacious treatment for intracranial aneurysms, but there is paucity of data for their use in the treatment of unruptured AComm aneurysms. We present the largest multicentric analysis evaluating the outcomes of flow diverters in AComm aneurysm treatment.
Databases from 10 centers were retrospectively reviewed for unruptured AComm aneurysms treated with flow diverters. Demographics, clinical presentation, radiographic characteristics, procedural complications, and outcomes were assessed.
A total of 144 patients harboring 147 AComm aneurysms were treated between January 2012 and December 2021. Seventy-four were women (51.4%) and median age was 60 (IQR 50-67) years. All were unruptured AComm aneurysms. Half of the cohort had similar anterior cerebral artery sizes (51.4%). The most common morphology was saccular (94.6%), with a branch involvement in 32.7% of cases. Median vessel diameter was 2.4 mm, and the Pipeline Flex was the most prevalent device (32.7%). Median follow-up time was 17 months, with complete occlusion in 86.4% at the last follow-up. Functional independence (modified Rankin Scale score 0-2) was reported in 95.1%. Intraprocedural complications occurred in 5.6%, and postoperative complications were noted in 9.7% of cases. Combined major complication and mortality rate was 2.1%.
Our study suggests that flow diverters are a useful treatment for AComm aneurysms. Mid-term results indicated favorable aneurysm occlusion with a good safety profile. Additional prospective studies with longer follow-up periods and independent adjudication are warranted to better assess these results.
前交通动脉(AComm)区域是颅内动脉瘤最常见的部位,与其他部位相比,破裂风险增加。总的来说,血流导向装置是颅内动脉瘤安全有效的治疗方法,但关于其在未破裂 AComm 动脉瘤治疗中的应用数据较少。我们报告了最大的多中心分析,评估了血流导向装置在 AComm 动脉瘤治疗中的结果。
回顾性分析了 10 个中心的数据库,纳入接受血流导向装置治疗的未破裂 AComm 动脉瘤患者。评估了患者的人口统计学、临床表现、影像学特征、手术并发症和结局。
2012 年 1 月至 2021 年 12 月期间,共治疗了 144 例患者的 147 个 AComm 动脉瘤。74 例为女性(51.4%),中位年龄为 60 岁(IQR 50-67 岁)。所有患者均为未破裂 AComm 动脉瘤。有一半的患者 AComm 动脉大小相似(51.4%)。最常见的形态为囊状(94.6%),其中 32.7%的病例存在分支受累。中位血管直径为 2.4mm,最常见的装置是 Pipeline Flex(32.7%)。中位随访时间为 17 个月,末次随访时完全闭塞率为 86.4%。95.1%的患者报告功能独立(改良Rankin 量表评分为 0-2)。术中并发症发生率为 5.6%,术后并发症发生率为 9.7%。主要并发症和死亡率合并发生率为 2.1%。
我们的研究表明,血流导向装置是 AComm 动脉瘤的一种有用的治疗方法。中期结果表明,动脉瘤闭塞效果良好,安全性好。需要进行更多前瞻性研究,随访时间更长,并进行独立评估,以更好地评估这些结果。